06:14
AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action
Broadcast Date
Presenter
Michael Heffernan, MD, PhD, FRCPC, FACC
Therapeutic Area
Cardiovascular
Dr. Michael Heffernan summarizes the role of PCSK9 in ASCVD and two approaches to PCSK9 inhibition: monoclonal antibodies (mAbs) and small interfering RNA (siRNA), describing their different mechanisms of action.
